{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:14:17Z","timestamp":1791472457291,"version":"4.3.4"},"reference-count":47,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DDDT"],"DOI":"10.2147\/dddt.s216056","type":"journal-article","created":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T00:09:32Z","timestamp":1586390972000},"page":"1391-1400","source":"Crossref","is-referenced-by-count":19,"title":["<p>Update on Eluxadoline for the Treatment of Irritable Bowel Syndrome with Diarrhea: Patient Selection and Perspectives<\/p>"],"prefix":"10.2147","volume":"Volume 14","author":[{"given":"Rebecca","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4925-4290","authenticated-orcid":true,"given":"Kyle","family":"Staller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,4]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1056\/NEJMra1607547","volume":"376","author":"Ford","year":"2017","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.cgh.2012.02.029","volume":"10","author":"Lovell","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1053\/gast.2000.16484","volume":"119","author":"Gralnek","year":"2000","journal-title":"Gastroenterology"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1038\/s41395-018-0262-x","volume":"113","author":"Frandemark","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"345","DOI":"10.2147\/JIR.S174982","volume":"11","author":"Ng","year":"2018","journal-title":"J Inflamm Res"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S2468-1253(16)30023-1","volume":"1","author":"Holtmann","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1053\/j.gastro.2016.02.032","volume":"150","author":"Drossman","year":"2016","journal-title":"Gastroenterology"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1053\/j.gastro.2016.02.031","volume":"150","author":"Lacy","year":"2016","journal-title":"Gastroenterology"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1177\/1756283X16663396","volume":"10","author":"Lucak","year":"2017","journal-title":"Therap Adv Gastroenterol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3109\/00365528709091004","volume":"130","author":"Hovdenak","year":"1987","journal-title":"Scand J Gastroenterol Suppl"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3109\/00365528709091003","volume":"22","author":"Lavo","year":"1987","journal-title":"Scand J Gastroenterol Suppl"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41395-018-0084-x","volume":"113","author":"Ford","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2165\/00023210-200115030-00006","volume":"15","author":"Wagstaff","year":"2001","journal-title":"CNS Drugs"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1111\/j.1365-2982.2012.01945.x","volume":"24","author":"Sohn","year":"2012","journal-title":"Neurogastroenterol Motil"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1111\/jcpt.12749","volume":"43","author":"Ng","year":"2018","journal-title":"J Clin Pharm Ther"},{"key":"ref16","first-page":"90","volume":"114","author":"Balakina","year":"2014","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1586\/egh.09.72","volume":"4","author":"Lewis","year":"2010","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1177\/1756283X13491798","volume":"6","author":"Tong","year":"2013","journal-title":"Therap Adv Gastroenterol"},{"key":"ref19","unstructured":"US Food and Drug Administration. Highlights of prescribing information for lotronex (alosetron). FDA Label; 2008. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/021107s013lbl.pdf. Accessed December 3, 2019."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1053\/j.gastro.2014.09.002","volume":"147","author":"Chang","year":"2014","journal-title":"Gastroenterology"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1111\/ajg.2007.102.issue-8","volume":"102","author":"Krause","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1111\/j.1572-0241.2001.04128.x","volume":"96","author":"Lembo","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"ref23","unstructured":"US Food and Drug Administration. Highlights of Prescribing Information for Xifaxan (rifaximin). FDA Label; 2017. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/021361s023lbl.pdf. Accessed December 3, 2019."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1004409","volume":"364","author":"Pimentel","year":"2011","journal-title":"New Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1053\/j.gastro.2016.08.003","volume":"151","author":"Lembo","year":"2016","journal-title":"Gastroenterology"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1177\/2040622317714389","volume":"8","author":"Barshop","year":"2017","journal-title":"Ther Adv Chronic Dis"},{"key":"ref27","unstructured":"US Food and Drug Administration. Highlights of prescribing information for viberzi (eluxadoline). FDA Label; 2018. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/206940s006lbl.pdf. Accessed December 3 2019."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.regpep.2009.03.012","volume":"155","author":"Holzer","year":"2009","journal-title":"Regul Pept"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1111\/j.1476-5381.2012.02068.x","volume":"167","author":"Wade","year":"2012","journal-title":"Brit J Pharmacol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1053\/j.gastro.2013.04.006","volume":"145","author":"Dove","year":"2013","journal-title":"Gastroenterology"},{"key":"ref31","unstructured":"U.S. Food and. Drug Administration Center for Drug Evaluation and Research (CDER). In: Guidance for Industry, Irritable Bowel Syndrome \u2014 Clinical Evaluation of Drugs for Treatment; May 2012."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1056\/NEJMoa1505180","volume":"374","author":"Lembo","year":"2016","journal-title":"N Engl J Med"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1111\/apt.14031","volume":"45","author":"Chey","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/ajg.2017.72","volume":"112","author":"Lacy","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.14309\/ajg.0000000000000327","volume":"114","author":"Brenner","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/gutjnl-2018-318160","volume":"69","author":"Black","year":"2019","journal-title":"Gut"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/ajg.2016.542","volume":"112","author":"Cash","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"ref38","unstructured":"US Food and Drug Administration. FDA Drug Safety Communication: FDA Warns About Increased Risk of Serious Pancreatitis with Irritable Bowel Drug Viberzi (Eluxadoline) in Patients Without a Gallbladder. Center for Drug Evaluation and Research; 2017. Available from: https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm546154.htm. Accessed December 3, 2019."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.cgh.2017.08.006","volume":"16","author":"Gawron","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.cgh.2017.11.025","volume":"16","author":"Chedid","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1111\/apt.14504","volume":"47","author":"Harinstein","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnut.2017.00001","volume":"4","author":"Afghani","year":"2017","journal-title":"Front Nutr"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1038\/ajg.2017.249","volume":"112","author":"Croteau","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/jcph.442","volume":"55","author":"Davenport","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.cgh.2017.01.026","volume":"15","author":"Fant","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1124\/jpet.116.236547","volume":"359","author":"Levy-Cooperman","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1756284819841290","DOI":"10.1177\/1756284819841290","volume":"12","author":"Lacy","year":"2019","journal-title":"Therap Adv Gastroenterol"}],"container-title":["Drug Design, Development and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=57324","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=57324","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T00:09:37Z","timestamp":1586390977000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/update-on-eluxadoline-for-the-treatment-of-irritable-bowel-syndrome-wi-peer-reviewed-article-DDDT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":47,"URL":"https:\/\/doi.org\/10.2147\/dddt.s216056","relation":{},"ISSN":["1177-8881"],"issn-type":[{"value":"1177-8881","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4]]}}}